Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference
March 16 2017 - 4:05PM
March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company
focused on the development and commercialization of innovative drug
candidates for the treatment of human cancers, today announced that
James Dentzer, Chief Financial Officer and Chief Administrative
Officer, will present at the Oppenheimer & Co. Inc. 27th Annual
Healthcare Conference on March 21, 2017 at 2:10 p.m. Eastern Time
in New York.
A corresponding webcast of the presentation can
be accessed, both live and archived, by visiting:
https://www.veracast.com/webcasts/opco/healthcare2017/03110203347.cfm
The webcast will be archived shortly after the live event and
will be available for 90 days through June 19, 2017. It will also
be available for 30 days on the Investor Relations section of the
Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company seeking to
develop and commercialize innovative and effective drug candidates
for the treatment of human cancers, including its lead development
candidate, CUDC-907, which is being investigated in clinical
studies in patients with lymphomas and solid tumors. Curis is
also engaged in a broad collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of the PD1 and VISTA pathways, including PDL1/VISTA
antagonist CA-170, and oral small molecule antagonists of the PD1
and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well
as to molecules designed to inhibit the IRAK4 kinase, including
CA-4948. Curis is currently conducting a Phase 1 trial of
CA-170 in patients with advanced solid tumors and lymphomas. Curis
is also party to a collaboration with Genentech, a member of the
Roche Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma, and
are further developing Erivedge in other diseases including
idiopathic pulmonary fibrosis and myelofibrosis. For more
information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6597
jdentzer@curis.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Sep 2023 to Sep 2024